Treatment
Peripheral Blood Stem Cell clinical trials
We’re tracking 176 recruiting studies that include Peripheral Blood Stem Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT04684368RecruitingPhase 2
New treatment study for children and young adults with NGGCT brain tumors
This Phase 2 study tests a new treatment approach for certain brain tumors called NGGCT in children and young adults. It may help improve outcomes by targeting tumors in specific brain locations and using tumor marker tests to guide care.
Birmingham, AlabamaAges 3–29 - NCT07582172RecruitingPhase 2
Stem Cell Transplant for Hard-to-Treat Blood Cancers in Older Adults
This trial tests a new combination of radiation and chemotherapy to prepare your body for a stem cell transplant from a matched donor. It's designed for older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that hasn't responded well to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Birmingham, AlabamaAges 18–75 - NCT07570407Recruiting
Blood Immune Cells After Bone Marrow Transplant for Leukemia
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
Pilsen, CzechiaAges 18–70 - NCT05088226RecruitingPhase 2
Ruxolitinib plus chidamide before transplant for high-risk leukemia
This Phase 2 study tests whether adding two medicines (ruxolitinib and chidamide) to a “conditioning regimen” before an allogeneic stem cell transplant improves outcomes for people with high-risk B-cell ALL. It may help prepare the body for transplant and reduce the chance of leukemia coming back.
Beijing, Beijing MunicipalityAges 12–65 - NCT01189786Recruiting
Stem cell transplant add-on that removes some immune cells
This trial tests a lab-made cell treatment added around an allogeneic stem cell transplant (donor transplant). It tries to improve transplant safety and outcomes by removing certain immune cells from the donor stem cells.
Houston, TexasAges Up to 70 years - NCT07702578RecruitingPhase 3
Study of special donor T-cells for blood stem cell transplant
This trial tests whether giving specially engineered donor T-cells after a stem cell transplant can help treat certain blood cancers like AML or MDS. The study is for people receiving a donor stem cell transplant for the first time.
Gilbert, ArizonaAges 18 years+ - NCT07362810RecruitingPhase 2
Adding IL-11 to G-CSF for faster blood cell recovery after transplant
This trial tests whether adding a second drug (IL-11) to the standard G-CSF can help your blood cells recover faster after a stem cell transplant using your own cells. It is for people with multiple myeloma or lymphoma who are about to have this transplant.
Zhengzhou, HenanAges 18–70 - NCT06569082Recruiting
Stem cell boost for poor graft function
This study tests whether giving extra stem cells from your original donor can help your blood cell counts recover after a transplant. It is for people whose new immune system has not fully engrafted or whose counts are dangerously low.
New York, New YorkAges 18 years+ - NCT06364150RecruitingPhase 3
Stem cell treatment for recent heart attack
This trial tests whether giving specially prepared stem cells from your own blood can help your heart recover after a heart attack. You must have had a successful angioplasty or stenting within the last 4 weeks.
SeoulAges 19–80 - NCT04008368RecruitingPhase 1/Phase 2
Second stem cell transplant for sickle cell with declining donor cells
This Phase 1/2 study tests whether repeating a stem cell transplant can help people with sickle cell disease (SCD) whose donor cells are no longer holding strong. It may help restore healthier blood cell production and reduce symptoms such as pain crises and severe anemia.
Bethesda, MarylandAges 2–80 - NCT07285668Recruiting
Special donor immune cells after stem cell transplant for high-risk blood cancers
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Madison, WisconsinAges 18–80 - NCT05473910RecruitingPhase 1
Engineered donor T cells after stem cell transplant for blood cancers
This trial tests specially engineered donor T cells (TSC-100 or TSC-101) given after a stem cell transplant to help prevent cancer relapse in people with AML, MDS, or ALL. It is for patients who have a specific genetic marker (HA-1 or HA-2) and a matched donor.
Duarte, CaliforniaAges 18 years+ - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03520647RecruitingPhase 2
Haplo transplant for severe bone marrow failure using donor cells
This trial tests a stem cell transplant from a closely matched but not fully matched family donor (haploidentical), with chemotherapy after the transplant to help prevent graft-versus-host disease (GVHD). It may help people with severe aplastic anemia, certain MDS after transformation, or PNH when other treatments have not worked or are not available.
Bethesda, MarylandAges 4–75 - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03801434RecruitingPhase 2
Ruxolitinib for people with certain eosinophil overgrowth diseases
This trial studies ruxolitinib to treat illnesses where the body makes too many eosinophils (a type of white blood cell) and symptoms or organ damage happen. It may help shrink disease activity when steroids are not enough, cannot be tolerated, or the illness comes back.
Palo Alto, CaliforniaAges 18 years+ - NCT03850366RecruitingPhase 2
Haploidentical stem cell transplant with two post-transplant medicines
This trial tests a way to treat certain blood cancers using a stem cell transplant from a partially matched (haploidentical) donor. It aims to make the transplant safer and reduce the chance of the immune reaction that can follow transplant, using post-transplant cyclophosphamide and bortezomib.
Detroit, MichiganAges 18–65 - NCT03964506RecruitingEarly Phase 1
Hyperbaric oxygen plus donor stem cell transplant for blood cancers
This early-phase trial studies whether breathing pure oxygen in a pressurized chamber, along with a donor stem cell transplant, can improve outcomes for certain blood cancers. It may help by supporting the body during transplant and recovery, but it is still being tested for safety and effectiveness.
Rochester, New YorkAges 18–75 - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT04224558RecruitingPhase 1/Phase 2
Stem cell transplant for hard-to-control Crohn’s disease
This early-phase study tests whether a stem cell transplant can improve Crohn’s disease in teens and young adults whose disease is active and not responding to standard medicines. It may help some people who are not doing well despite several prior treatments, but it also involves intensive study procedures and safety checks.
Los Angeles, CaliforniaAges 13–28 - NCT04370301RecruitingPhase 2
Reduced-intensity stem cell transplant with JAK inhibitor for myelofibrosis
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
Seattle, WashingtonAges 18–70 - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75 - NCT05294055RecruitingPhase 2
Mecapegfilgrastim to help collect stem cells for transplant
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
Hefei, AnhuiAges 18–65
What Peripheral Blood Stem Cell is being studied for
Conditions with recruiting Peripheral Blood Stem Cell studies.
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome With Excess Blasts
- Refractory Acute Lymphoblastic Leukemia
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Mixed Phenotype Acute Leukemia
- Refractory Mixed Phenotype Acute Leukemia
Common questions
- Are there clinical trials studying Peripheral Blood Stem Cell?
- Yes. Clin2 currently lists 176 recruiting studies that include Peripheral Blood Stem Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Peripheral Blood Stem Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Peripheral Blood Stem Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Peripheral Blood Stem Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.